A randomized, placebo-controlled phase I trial of live, attenuated herpes zoster vaccine in subjects with end-stage renal disease immunized prior to renal transplantation.

摘要: Background Solid organ transplant recipients are at increased risk for reactivation of herpes zoster, or shingles, and have a higher frequency serious complications including post-herpetic neuralgia. A live, attenuated shingles vaccine is effective approved individuals 50 years older. The contraindicated following transplantation, but may be used in patients with renal failure. Utilization the has been poor end-stage disease, those awaiting transplant, owing to concerns safety, efficacy, potential sensitization prior transplant. Methods We conducted phase I, randomized, placebo-controlled study safety immunogenicity Oka strain subjects 3 US centers. Subjects received minimum 4 weeks Results was safe well-tolerated. There were no cases zoster rash illness. change donor-specific antibody calculated panel reactive after vaccination during follow-up period. rejection episodes. significant 2.1-fold rise geometric mean titer anti-VZV 5 post-vaccine. Conclusions data suggest that ESRD Antibody responses similar seen previously adults >50 age consistent protective response.